Results 1 to 10 of about 958,101 (344)

In vitro efficacy of artemisinin-based treatments against SARS-CoV-2

open access: yesScientific Reports, 2021
Effective and affordable treatments for patients suffering from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are needed.
Yuyong Zhou   +13 more
doaj   +1 more source

Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro

open access: yesViruses, 2021
We report the in vitro efficacy of ion-channel inhibitors amantadine, memantine and rimantadine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Yuyong Zhou   +7 more
doaj   +1 more source

SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor

open access: yesVaccines, 2021
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has demonstrated the value of pursuing different vaccine strategies. Vaccines based on whole viruses, a widely used vaccine technology, depend on efficient virus production.
Anna Offersgaard   +14 more
doaj   +1 more source

Chronic hepatitis C elimination prison initiative: HCV‐intensive test and treat, a whole prisoner population HCV test‐and‐treat program in England

open access: yesHealth Science Reports, 2023
Background and Aim Prison residents are at high risk for hepatitis C virus (HCV) infection. HCV test‐and‐treat initiatives within prisons provide an opportunity to engage with prison residents and achieve HCV micro‐elimination.
Rachel Halford   +9 more
doaj   +1 more source

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir

open access: yesViruses, 2023
Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in development.
Karen Anbro Gammeltoft   +11 more
doaj   +1 more source

Identification of Novel Determinants of Neutralization Epitope Shielding for Hepatitis C Virus in Vitro

open access: yesProceedings, 2020
Epitope shielding is suggested as an important mechanism mediating the escape of hepatitis C virus (HCV) from host-neutralizing antibodies (nAb). [...]
Garazi Peña Alzua   +10 more
doaj   +1 more source

Association of TM6SF2 rs58542926 T/C gene polymorphism with hepatocellular carcinoma: a meta-analysis

open access: yesBMC Cancer, 2019
Background Hepatocellular carcinoma (HCC) is the sixth-most common malignancy worldwide. Multiple previous studies have assessed the relationship between TM6SF2 gene polymorphism and the risk of developing HCC, with discrepant conclusions reached.
Shan Tang   +13 more
doaj   +1 more source

Prognosis and therapeutic benefits prediction based on NK cell marker genes through single-cell RNA-seq with integrated bulk RNA-seq analysis for hepatocellular carcinoma

open access: yesFrontiers in Oncology, 2023
Tumor-infiltrating immune cells greatly participate in regulating tumorigenesis and metastasis of hepatocellular carcinoma (HCC). Natural killer cell, as an important role of innate immunity, plays an indispensable role in antitumor immunity and regulate
Yao Yang   +5 more
doaj   +1 more source

Hepatitis C [PDF]

open access: yesDiagnóstico, 2018
El virus de hepatitis C (VHC) es un virus monocatenario ARN perteneciente al género Hepacivirus de la familia Flaviviridae. En la década de 1970, tras el descubrimiento de hepatitis A y B, se hizo claro que había casos de hepatitis post-transfusión que no podían ser explicados por estos virus, llevando a la descripción de hepatitis ''no A, no B''.
Calmet Schwartzmamn , Fernando H.   +1 more
openaire   +4 more sources

The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019

open access: yesFrontiers in Public Health, 2023
Background and aimHepatitis C virus infection can lead to an enormous health burden worldwide. Investigating the changes in HCV-related burden between different countries could provide inferences for disease management.
Jia Yang   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy